Legal & General Group Plc bought a new position in Pulse Biosciences, Inc (NASDAQ:PLSE – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,240 shares of the company’s stock, valued at approximately $395,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. BNP Paribas Financial Markets boosted its stake in Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after acquiring an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. raised its position in Pulse Biosciences by 44.0% in the third quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after acquiring an additional 1,372 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Pulse Biosciences in the 2nd quarter valued at about $290,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Pulse Biosciences during the 2nd quarter valued at about $158,000. Institutional investors own 76.95% of the company’s stock.
Pulse Biosciences Price Performance
NASDAQ PLSE opened at $48.79 on Wednesday. The firm has a market capitalization of $3.38 billion, a price-to-earnings ratio of -41.35 and a beta of 1.63. The company has a 50 day simple moving average of $38.88 and a 200-day simple moving average of $28.41. Pulse Biosciences, Inc has a 52-week low of $12.56 and a 52-week high of $55.37.
Insider Buying and Selling at Pulse Biosciences
In related news, COO Liane Teplitsky purchased 1,036 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were acquired at an average cost of $48.23 per share, with a total value of $49,966.28. Following the completion of the purchase, the chief operating officer owned 1,036 shares of the company’s stock, valued at $49,966.28. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired 4,095 shares of company stock valued at $199,931 over the last 90 days. Corporate insiders own 74.00% of the company’s stock.
Analyst Upgrades and Downgrades
PLSE has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Canaccord Genuity Group upped their price target on Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a report on Monday, August 10th. Mizuho set a $45.00 price objective on Pulse Biosciences in a research report on Monday, August 10th. Finally, Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $45.25.
Read Our Latest Stock Analysis on PLSE
Pulse Biosciences Company Profile
Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.
The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.
Read More
- Five stocks we like better than Pulse Biosciences
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Want to see what other hedge funds are holding PLSE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulse Biosciences, Inc (NASDAQ:PLSE – Free Report).
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
